Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

dimethyl glutamate

- PMLiVE

Biogen under fire over $88,000 Vumerity annual price

Pricing pressure levelled at Tecfidera follow-up MS drug

- PMLiVE

Biogen takes on Lucentis, Eylea biosimilars from Samsung joint venture

Will pay $100m upfont and pledges $210m in milestone payments

- PMLiVE

Sanofi settles Lemtrada dispute with Genzyme investors for $315m

The MS drug has been in decline amid increased market competition

- PMLiVE

Biogen and Eisai revive abandoned aducanumab in shock turnaround

Companies plan to file the deserted Alzheimer’s drug with FDA

- PMLiVE

Biogen’s R&D chief Ehlers heads for the exit

Follows multiple late-stage Alzheimer's study failures

- PMLiVE

Biogen loses another pipeline drug to toxicity concerns

Follows discontinuation of Eisai-partnered Alzheimer's drug

- PMLiVE

New data backs GeNeuro’s MS drug after Servier exit

Search continues for new development partner

- PMLiVE

Biogen and Eisai drop Alzheimer’s drug elenbecestat

Latest blow in string of failures for BACE inhibitor category

- PMLiVE

Merck takes evobrutinib for MS into phase 3, on mixed data

First drug in class to reach this stage for the illness

- PMLiVE

Tecfidera successor’s side-effect profile boosts Biogen

But analysts unconvinced that patients will switch

- PMLiVE

Biogen grows in Q2, but Spinraza performance a concern

Company banking on pipeline readouts and Tecfidra defence

The role of brain health in treating MS

Blue Latitude Health speaks to Professor Gavin Giovannoni, key opinion leader and Chair of Neurology, Barts and The London School of Medicine and Dentistry, about his theories on brain health,...

Blue Latitude Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links